GlassScriptPhysician profile
Thomas S Royster
NPI 1730221441
$4,062.36
in general payments reported to CMS, 2019-2025
38 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $620 · 2021: $952 · 2022: $676 · 2023: $408 · 2024: $394 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.87 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Antares Pharma, INC. | $574.07 | 2019-2025 | Xyosted, Tlando |
| Novo Nordisk INC | $351.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $330.37 | 2019-2024 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $327.85 | 2019-2022 | |
| Lilly USA, LLC | $258.30 | 2022-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $170.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $140.42 | 2019-2021 | |
| Amgen INC. | $125.30 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $111.88 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $104.41 | 2019-2023 | Belsomra |
| Astellas Pharma US INC | $85.03 | 2019-2022 | |
| Clarus Therapeutics INC. | $75.50 | 2021 | |
| Tolmar, INC. | $74.71 | 2023-2025 | Jatenzo |
| Eisai INC. | $62.78 | 2020-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Royster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.